Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gynecologic Oncology

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2016.07.088PMID 27444036PMCID PMC5031537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects

  2016cited by this paper
• Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Whole–genome characterization of chemoresistant ovarian cancer

  2015cited by this paper
• Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

  2015cited by this paper
• Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

  2014cited by this paper
• Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System

  2014cited by this paper
• Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

  2014cited by this paper
• Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

  2014cited by this paper
• The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer

  2014cited by this paper
• Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts

  2014cited by this paper
• Evaluating cell lines as tumour models by comparison of genomic profiles

  2013cited by this paper
• Profile of panobinostat and its potential for treatment in solid tumors: an update

  2013influential reference
• Synthetic lethality between CCNE1 amplification and loss of BRCA1

  2013influential reference
• Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer

  2013cited by this paper
• Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma

  2013cited by this paper
• BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.

  2012cited by this paper
• CA : A Cancer Journal for Clinicians

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells

  2011cited by this paper
• Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer

  2010cited by this paper
• Residual γH2AX foci as an indication of lethal DNA lesions

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Hdac3 is essential for the maintenance of chromatin structure and genome stability.

  2010cited by this paper
• Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• DNA fingerprinting of the NCI-60 cell line panel

  2009cited by this paper
• Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control.

  2008cited by this paper
• Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation

  2007cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Cyclin E and Its Low Molecular Weight Forms in Human Cancer and as Targets for Cancer Therapy

  2003cited by this paper
• XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

  1999cited by this paper
• Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations.

  1998cited by this paper
• Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.

  1998cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Preliminary study of apatinib combined with fluzoparib in the treatment of HRP ovarian cancer via the HR pathway

  2025cites this paper
• TTK activates ATR through RPA2 phosphorylation to promote olaparib resistance in ovarian cancer

  2025cites this paper
• The effect of PARP and PLK1 dual inhibition on the expression of important protein signaling pathways, DNA damage, and molecular docking scores against MCF-7 and MDA-MB-231 breast cancer cell lines.

  2025cites this paper
• The translational potential of epigenetic modulatory bioactive phytochemicals as adjuvant therapy against cancer.

  2025cites this paper
• Clinical Applications of HDAC Inhibitors as Anticancer Agents in Prostate, Breast, Ovarian, and Cervical Cancers

  2025cites this paper
• Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer

  2024cites this paper
• A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity

  2024cites this paper
• Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group

  2024cites this paper
• Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib

  2024cites this paper
• Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer

  2023cites this paper
• The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities

  2023cites this paper
• Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses.

  2023cites this paper
• DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities

  2023cites this paper
• The paradigm of drug resistance in cancer: an epigenetic perspective

  2022cites this paper
• Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition

  2022cites this paper
• Multifaceted Influence of Histone Deacetylases on DNA Damage Repair: Implications for Hepatocellular Carcinoma

  2022cites this paper
• Chloroquine-Induced DNA Damage Synergizes with Nonhomologous End Joining Inhibition to Cause Ovarian Cancer Cell Cytotoxicity

  2022cites this paper
• Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer

  2021cites this paper
• Histone Modifying Enzymes in Gynaecological Cancers

  2021cites this paper
• Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors

  2021cites this paper
• Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.

  2021cites this paper
• Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair

  2021cites this paper
• Ovarian cancer: epigenetics, drug resistance, and progression

  2021cites this paper
• DNA double-strand break repair in cancer: A path to achieving precision medicine.

  2021cites this paper
• Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time

  2021cites this paper
• Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations

  2021cites this paper
• Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer

  2021cites this paper
• Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas

  2020cites this paper
• Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

  2020cites this paper
• Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer

  2020cites this paper
• CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes

  2020cites this paper
• Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer.

  2019cites this paper
• Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer

  2019cites this paper
• PARP inhibitors in ovarian cancer.

  2019cites this paper
• The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

  2018cites this paper
• PARP inhibitors as precision medicine for cancer treatment

  2017cites this paper
• PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.

  2017cites this paper
• Fanconi Anemia Signaling and Cancer.

  2017cites this paper